A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer

Clinical Cancer Research

Volumn 7, Issue 6, 2001, Pages 1590-1599

  Shapiro, Geoffrey I ^a   Lynch, Cathy ^a   Lucca, Joan ^a   Zacarola, Patrick F ^a   Rollins, Barrett J ^a   Supko, Jeffrey G ^b   Patterson, Angus ^b   Muzikansky, Alona ^b   Lynch, Thomas J ^b   Wright, John J ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b General Hospital Cancer Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VEIN THROMBOSIS;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FLAVONOIDS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PIPERIDINES; TIME FACTORS;

EID: 0034900178     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
2. First-line combination chemotherapy for advanced nonsmall cell lung cancer: The Eastern Cooperative Oncology Group and Southwest Oncology Group experience
3. A family of human cdc2-related protein kinases
4. Cyclin D1 overexpression vs. Retinoblastoma inactivation: Implications for growth control evasion in non-small cell and small cell lung cancer
5. INK4 expression in primary lung cancers and cell lines
6. 1 control gene status is frequently altered in resectable non-small cell lung cancer
7. Disruption of the Rb pathway and cell-proliferative activity in non-small cell lung cancers
8. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer
9. INK4A/CDKN2A tumor suppressor and its relatives
10. WAFI, a potential mediator of p53 tumor suppression
11. Prognostic role of the cyclin-dependent kinase inhibitor p27 in nonsmall cell lung cancer
12. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
13. INK4 gene mediated by an adenovirus vector
14. Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27
15. Kip1 overexpression causes apoptotic death of mammalian cells
16. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
17. Kip1 in inducing cell cycle arrest, apoptosis, and inhibition of tumorigenicity
18. INK4-mediated apoptosis in non-small cell lung cancer cells
19. INK4A in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression, and tumor regression
20. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
21. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
22. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
23. Havopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
24. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines
25. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275
26. 1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells
27. Cell cycle-independent induction of apoptosis by the antitumor drug flavopiridol in endothelial cells
28. Flavopiridol binds to duplex D.N.A
29. Novel small molecule αv integrin antagonists: Comparative anticancer efficacy with known angiogenesis inhibitors
30. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
31. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol
32. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site
33. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
34. Phase I clinical and pharmacokinetic trial of flavopiridol. Proc
35. Preparation of mean drug concentration-time curves in plasma: A study on the frequency distribution of pharmacokinetic parameters
36. The jackknife-a review
37. Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed?
38. Optimal two-stage designs for Phase II clinical trials
39. Nonparametric estimation from incomplete observations
40. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
41. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II consortium study
42. The cyclin-dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer
43. Phase II trial of flavopiridol in metastatic colorectal cancer: Preliminary results
44. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
45. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
46. Phase II study of topotecan in metastatic non-small cell lung cancer
47. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
48. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
49. Potentiation of flavopiridol-mediated apoptosis in non-small cell lung cancer cell lines following recruitment of cells to S phase
50. A Phase I trial of 1-hour infusion of flavopiridola novel cyclin-dependent kinase inhibitor, in patients with advanced neoplasms
51. Pharmacokinetics (PK) of flavopiridol IV bolus in patients with refractory neoplasms
52. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein
53. INK4A expression in resected non-small cell lung tumors
54. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: An immunohistochemical study
55. INK4B/MTS2, and F18 genes in primary and metastatic lung cancer
56. Differential inactivation of CDKN2 and Rb protein in non-small cell and small-cell lung cancer cell lines
57. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage
58. INK4A inactivation in non-small cell lung cancers
59. A randomized Phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
60. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
61. Sequential-dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
62. Anticancer drug targets: Cell cycle and checkpoint control
63. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol
64. Potent interaction of flavopiridol with MRP1
65. Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol (flavo) in patients with advanced solid tumors